↓ Skip to main content

PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.

Overview of attention for article published in Journal of Clinical Oncology, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

news
1 news outlet

Readers on

mendeley
4 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
Published in
Journal of Clinical Oncology, May 2018
DOI 10.1200/jco.2018.36.15_suppl.tps5612
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Other 2 50%
Student > Ph. D. Student 1 25%
Researcher 1 25%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 50%
Environmental Science 1 25%
Medicine and Dentistry 1 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2021.
All research outputs
#4,251,502
of 23,136,540 outputs
Outputs from Journal of Clinical Oncology
#7,883
of 20,189 outputs
Outputs of similar age
#83,001
of 329,570 outputs
Outputs of similar age from Journal of Clinical Oncology
#178
of 531 outputs
Altmetric has tracked 23,136,540 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,189 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.7. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,570 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 531 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.